Insulin 338

Drug Profile

Insulin 338

Alternative Names: Insulin oral (NN 1953); Insulin-338-GIPET-I; LAI 338; NN 1438; NN-1953; NNC-0123-0000-0338; NNC0123-0338; OI-338GT; Oral insulin 338 C10

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Type 1 diabetes mellitus; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Feb 2016 Phase-II clinical trials in Type-1 diabetes mellitus in Germany (PO) prior to February 2016 (Novo Nordisk's pipeline, February 2016)
  • 01 Dec 2015 Novo Nordisk completes a phase II trial for Type-2 diabetes mellitus in Germany (NCT02470039)
  • 11 May 2015 Phase-II clinical trials in Type-2 diabetes mellitus in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top